Fortrea Holdings Inc. is a biotechnology company focused on developing and commercializing innovative therapeutics for unmet medical needs, particularly in the fields of oncology and rare diseases. The company leverages advanced scientific research and technology to create transformative treatment options that aim to improve patient outcomes and quality of life. Through a combination of cutting-edge drug development and strategic partnerships, Fortrea Holdings is dedicated to bringing new therapies to market while adhering to rigorous safety and efficacy standards in the healthcare industry. Read More
In a financial landscape often dictated by strict adherence to earnings forecasts, recent market movements have showcased a fascinating deviation from traditional expectations. Public companies like Fortrea Holdings (NASDAQ: FTRE) and Flowco Holdings (NYSE: FLOC) have seen their stock prices surge, even in the face of missed earnings per share
Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 CY2025, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue guidance of $2.73 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 25.7% below analysts’ consensus estimates.
Fortrea posts Q3 2025 results with a revenue beat but an adjusted EPS miss. The CRO raises its full-year revenue guidance and reports a strong book-to-bill ratio of 1.13x.
Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Rapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE)
jumped 7.7% in the afternoon session after it commenced a cash tender offer to buy back up to $75.74 million of its outstanding senior secured notes. The offer targeted the company's 7.500% Senior Secured Notes that are due in 2030. This action was taken to comply with the rules tied to the net proceeds from the company's sale of its Fortrea Patient Access and Endpoint Clinical businesses, which was completed in a previous June. By using cash on hand to repurchase its debt, the company signaled financial discipline and effective balance sheet management. Investors often view such moves positively as they can reduce interest expenses and demonstrate a company's confidence in its financial health, which likely contributed to the stock's rise.
DURHAM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it has commenced a debt tender offer (the “Tender Offer”) to purchase for cash up to $75,744,000 (the “Maximum Amount”) in aggregate purchase price of the Company’s outstanding 7.500% Senior Secured Notes due 2030 (each, a “Note” and collectively, the “Notes”).
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fortrea Holdings, Inc. (NasdaqGS: FTRE).
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE)
jumped 6.1% in the afternoon session after Evercore ISI Group raised its price target on the company to $11.00 from a previous $7.00.
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE)
fell 6.3% in the afternoon session after negative news weighed on the broader healthcare sector, including a new U.S. government investigation into medical equipment imports. The U.S. Commerce Department initiated an investigation into the national security implications of importing a wide range of healthcare products, from surgical masks to pacemakers. This review raised the possibility of future tariffs or quotas on these goods.
DURHAM, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on September 12, 2025, to one newly hired employee. The award consisted of 75,000 RSUs that vest in three equal annual installments starting September 12, 2026, subject to the employee’s continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company’s Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an inducement material to the individual becoming a new employee of the Company.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE)
jumped 4.5% in the afternoon session after Baird raised its price target on the stock to $14.00. This positive analyst action adds to a broader shift in sentiment for the clinical research organization. According to recent data covering six analysts, the average 12-month price target for Fortrea has risen by nearly 20% to $8.00, with a high estimate now matching Baird's at $14.00.
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts.
But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
